Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?
Sujit V Janardhan, Nancy S Reau Center for Liver Diseases, Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, IL, USA Abstract: Chronic hepatitis C virus (HCV) infection represents a global health problem that affects up to 130–...
Guardado en:
Autores principales: | , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b87ffaa4cb8b4d57b149574f3fe3c7a4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|